For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News) — For ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...

The researchers revealed that GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...